PPT-HIFU Dr Prashant Bansal Two basic forms of thermal therapy for treatment of prostate cancer

HighIntensity Focused Ultrasound which uses focused sound energy to heat tissue to destroy it HIFU is different from cryotherapy in that the focal zone is extremely discrete with little or no tissue effects in areas immediately adjacent to the treatment zone. Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. 1. e targeted prostatic volume is localized with a transrectal ultrasound imaging probe.Proceduree patient will be asked to come into hospital/surgery center the day of the procedure. He will ne is oering a new, minimally invasive alternative for treating prostate cancer — high-intensity focused ultrasound (HIFU) — which uses sound waves to selectively target and destroy dis and Non-Invasive HIFU Treatment HIFU: The prostate cancer treatment focused on a higher quality of life HIFUProstateServices.com HIFU for Prostate Cancer High Intensity Focused Ultrasound Duke University, BA Chemistry 1994Duke University, MD 1999University of California, San Francisco (UCSF) 1999-2001 General SurgeryUniversity of California, San Francisco (UCSF) 2001-2005 UrologyThe Am is o31ering a new minimally invasive alternative for treating prostate cancer 151 high-intensity focused ultrasound HIFU 151 which uses sound waves to selectively target and destroy diseased tissueUC Background A National Institutes of Health NIH panel that convened in 2011 recommended that AS151a strategy with curative intent that involves regular monitoring of PSA levels and repeat biopsies151sh Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical Program Director of Genitourinary Cancers, Inova . Schar. Cancer Institute. Associate Professor of Medicine, Virginia Commonwealth University. October 18, 2019. Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, Medical Director. Vituro Health. HIFU: Technical Pearls Part I. Stephen Scionti, MD. Medical Director. Vituro. Health. HIFU FDA Approval. October 9, 2015. : SonaCare Medical: Sonablate device: . de novo . Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. By: Ishan Parikh. Symptoms. Be on the look out for…. “stop-and-go” flow of urine. Sudden urges to urinate. Frequent urination (esp. at nights). Trouble starting urination. Trouble with emptying bladder completely. NASPCC 10-13-18. Ronald Chen, MD MPH. Associate Professor, Radiation Oncology. University of North Carolina – Chapel Hill. Associate Director, UNC Lineberger Comprehensive Cancer Center. Disclosures.